Author: Donald McLean

Cliniphai and Gibson Research Consultancy Partner to Streamline Global COA and eCOA Translation Workflows

Written by Donald McLean on September 9, 2025. Posted in News. No Comments on Cliniphai and Gibson Research Consultancy Partner to Streamline Global COA and eCOA Translation Workflows

GREAT FALLS, Montana and LONDON (September 9, 2025) — Cliniphai, an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, announced a strategic partnership with Gibson Research Consultancy (GRC), a global leader in health communication, patient voice research, linguistic validation and patient-centered research for Clinical Outcome Assessments (COA and eCOA) and other related health information and patient-facing documents. The partnership brings together GRC’s world-class expertise and Cliniphai’s AI-powered Athena™ platform to redefine how translation and localization services are delivered across clinical trials.

GRC has provided services for nearly every top pharmaceutical company, with over 11,000 COA and eCOA validation projects completed across more than 250 languages and more than 190 countries and territories. Under this new collaboration, GRC will perform its full suite of linguistic validation services directly through Cliniphai’s Athena platform.

Work has already begun, with GRC teams actively managing studies through Athena’s centralized environment. The platform enables project visibility, version tracking, ISPOR-compliant workflows, and integrated QA monitoring to provide both service providers and sponsors with greater control and confidence across timelines and geographies.

“This partnership is the clearest signal yet of how AI can support trusted experts in delivering global outcomes,” said Jason Martin, MS, MBA, Chairman and Co-Founder at Cliniphai. “GRC has set the global standard for COA translation excellence, and Athena provides the tools they need to deliver at scale with structure, speed, and quality.”

Delivering clinical translations at scale pharma and biotech

Athena is Cliniphai’s flagship AI-powered platform for clinical translation and localization, now operating as a marketplace model to support collaboration across sponsors, eCOA providers, freelance language experts, and reviewers. The platform is purpose-built for life sciences and delivers:

AI-assisted clinical translation workflows with human-in-the-loop steering
Adaptive, context-aware translation with support for dialects and terminology control
Centralized version tracking, QA checkpoints, and real-time progress visibility
Built-in ISPOR-compliant workflows and automated Certificate of Translation support
Seamless integration with existing systems through secure APIs
Flexible private cloud solutions designed to align with customer-specific security, infrastructure, and compliance standards
Marketplace functionality to connect clinical teams with qualified language professionals
Operational transparency and structured collaboration across global study teams

“The first time I saw Athena, I recognized its potential immediately,” said Mark Gibson, MA, Founder, GRC. “Cliniphai created something original that brings clarity and structure to clinical translation workflows in a way we had not seen before. I am proud to partner with a team that understands the importance of both innovation and execution in this space.”

Athena is designed to reduce delays, eliminate manual tracking, and support accurate, compliant translations across every phase of clinical development. To explore Athena’s marketplace model or work with the team, visit https://cliniphai.com/solutions/athena/.

About Cliniphai

Cliniphai is an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences. Its flagship solution, Athena, is a marketplace-driven platform for clinical translation and localization that combines AI-powered workflows with built-in compliance and operational transparency. Designed to support sponsors, CROs, eCOA providers, and language experts alike, Athena enables secure, scalable, and collaborative execution across global studies. For more, visit www.cliniphai.com.

About Gibson Research Consultancy (GRC)

Founded in 2008 by Mark Gibson, GRC is a global leader in health communication, patient voice research, linguistic validation and patient-centered research for COA and eCOA and other related health information and patient-facing documents. Based in Leeds, United Kingdom, GRC supports multi-country studies across more than 250 languages through a trusted network of regulatory, linguistic, and research partners. The team brings more than two decades of experience in qualitative research and multilingual testing, with a proven ability to complete projects in rarer, creole, minority, and indigenous languages. GRC’s commitment to clarity, accuracy, and user relevance has made it a trusted partner to nearly every top pharmaceutical company worldwide. For more, visit: https://www.grc-health.com/.

Media Contacts

Don F. McLean, McLean Media
+1-734-716-4162

###

Cliniphai Unveils Marketplace Model for Athena Clinical Translation and Localization Platform at BIO 2025 in Boston, Company Appoints Michael Arbitman as Executive Chief of Staff to Accelerate Platform Execution

Written by Donald McLean on June 16, 2025. Posted in News. No Comments on Cliniphai Unveils Marketplace Model for Athena Clinical Translation and Localization Platform at BIO 2025 in Boston, Company Appoints Michael Arbitman as Executive Chief of Staff to Accelerate Platform Execution

Cliniphai, an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, today announced the next phase of its flagship platform, Athena, at the BIO International Convention 2025. Building on the powerful workbench for clinical trial localization, Athena expands its services to create a total marketplace model designed to connect eCOA providers, translation freelancers, and clinical trial sponsors, among numerous others, in a unified ecosystem.

This evolution transforms Athena from a standalone solution into a connected platform where compliance, efficiency, global collaboration, and scalable execution converge. By aligning AI workflows with regulatory standards and integrating end-to-end tracking, Athena delivers a seamless, transparent experience that accelerates multilingual clinical trial operations.

“This update is a step forward for how regulated translation can operate in the clinical research industry overall,” said Jason Martin, MS, MBA, Chairman and Co-Founder at Cliniphai. “Athena now brings translators, reviewers, and life sciences teams into one connected system. It’s a smarter model that supports better outcomes across global studies.”

Athena’s new marketplace allows organizations to:

Engage qualified translation experts within the platform
Track version history and QA across language pairs
Maintain ISPOR-compliant workflows with built-in checkpoints
Eliminate vendor threads and siloed document tracking
Accelerate time-to-launch for global studies with flexible engagement options

The platform is built to support the real-world needs of eCOA vendors managing multilingual content, sponsors navigating global submissions, and qualified translators seeking structured, high-value work in regulated settings.

Leadership growth continues at Cliniphai

To support this next chapter, Cliniphai has appointed Michael Arbitman as Executive Chief of Staff. Formerly a top-level executive with Medidata, CARET Legal, and Fresh Direct, Arbitman brings decades of experience in product strategy, FDA-regulated systems, and Agile program delivery, and will lead execution across Athena’s growing marketplace environment

“I see a clear opportunity to help shape the future of Athena by building a strong operating model that supports global scale and regulatory clarity,” said Arbitman. “It’s a privilege to lead this work alongside a team that brings deep scientific and clinical expertise to every part of the platform.”

Arbitman is already leading implementation efforts on Athena for major global translation projects, including managing ISPOR-compliant Morisky Medication Adherence Scale (MMAS) workflows across five language pairs, country-specific PI reviewer coordination, and real-time QA reporting.

Cliniphai’s team will be at booth 1269 during BIO 2025 in Boston, connecting with partners across the translation, eCOA, and clinical technology space. To explore Athena’s marketplace model or speak with the team, visit www.cliniphai.com.

About Cliniphai

Cliniphai is an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences. Its flagship solution, Athena, is a marketplace-driven platform for clinical translation and localization that combines AI-powered workflows with built-in compliance and operational transparency. Designed to support sponsors, eCOA providers, and language experts alike, Athena enables secure, scalable, and collaborative execution across global studies. For more, visit www.cliniphai.com.

Media Contacts

Don F. McLean, McLean Media
+1-734-716-4162

###

Cliniphai Appoints Former Medidata Quality Head as Chief Compliance Officer to Strengthen Standards For AI-Powered Clinical Translation and Localization Tool

Written by Donald McLean on May 14, 2025. Posted in Uncategorized. No Comments on Cliniphai Appoints Former Medidata Quality Head as Chief Compliance Officer to Strengthen Standards For AI-Powered Clinical Translation and Localization Tool

Great Falls, Montana and Kyiv, Ukraine (May 14, 2025) – Cliniphai, an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, today announced the appointment of Donna Wallace, MBA as Chief Compliance Officer. Wallace, who joined in April, will oversee Cliniphai’s global compliance programs and quality management systems, playing a critical role in ensuring that the company’s AI-powered solutions meet the highest standards for safety, effectiveness, and regulatory adherence.

Cliniphai and Adherence Partner on Translation and Localization for Clinical Trial Endpoints and Patient-Facing Materials on World Adherence Day 2025

Written by Donald McLean on March 27, 2025. Posted in Uncategorized. No Comments on Cliniphai and Adherence Partner on Translation and Localization for Clinical Trial Endpoints and Patient-Facing Materials on World Adherence Day 2025

Great Falls, Mont. and Long Beach, Calif. (March 27, 2025) – Cliniphai, an AI Agent and Framework platform designed to solve complex challenges in life sciences, has announced a strategic partnership with Adherence, a digital health startup specializing in medication adherence predictive analytics. Adherence leverages real-world adherence data and behavioral insights to identify patterns, predict non-adherence risks, and drive targeted interventions. Through this collaboration, the two companies aim to expand access to high-quality adherence data, transforming how clinical translation and localization are implemented in global healthcare.

Starting today, Cliniphai’s Athena™ platform and the Adherence ATLAS™ (Adherence Tools and Location Analytics System) platform will come together to drive an unprecedented 24-hour global adherence initiative. ATLAS will collect and analyze more than 1,000 real-time adherence assessments from healthcare providers and patients across the world with support from Athena. In parallel, Cliniphai and Adherence are embarking on a landmark project to demonstrate how Athena’s human-guided, AI-augmented translation technology can streamline the localization of clinical trial endpoints and patient-facing materials to ensure faster timelines, greater cost-efficiency, and uncompromising clinical quality.

“This partnership represents a major step forward in advancing global adherence science and transforming how clinical trials engage diverse populations,” said Jason Martin, MS, MBA, Chairman and Co-Founder at Cliniphai. “Working alongside Philip Morisky and his team, we’re equally amplifying the reach and impact of the MMAS and demonstrating how Athena can redefine clinical translation by delivering high-quality, regulatory-compliant localizations with unprecedented speed, accuracy, and scale. Together, we’re setting a new standard for how life sciences organizations connect with patients and improve health outcomes worldwide.”

Raising the bar for global adherence and localization

The Morisky Medication Adherence Scale (MMAS) is a globally recognized, validated gold standard for measuring medication adherence in clinical trials and healthcare settings. As part of this collaboration, Cliniphai will localize MMAS condition-specific instruments into five additional languages, including Russian, Arabic, Chinese, Japanese, and French, with plans to expand to all 40 languages currently covered within the tool.

Key project objectives include:

Faster localization, with early beta testing showing a potential 3x increase in speed compared to traditional methods and measuring through complete end-to-end timelines.
Greater cost-efficiency, projecting a 2-3x reduction in cost for translation and localization processes for greater access and scalability.
Maintaining clinical equivalence and compliance, by upholding MMAS’s clinical validity through expert reviews, cognitive field testing, and co-validation by Dr. Morisky’s expert network. All work aligns with ISPOR standards and best practices in global health research.

“This partnership helps us strengthen the clinical application of MMAS globally and gives us the opportunity to further expand language capabilities to improve accessibility and global adoption,” said Philip Morisky, Chief Optimus of Adherence. “It also accelerates the development of Athena as a trusted platform that addresses the critical challenge of ensuring that language is never a barrier to better data, deeper insights, and improved patient outcomes. Together, we are laying the foundation for a more inclusive and effective approach to medication adherence worldwide.”

A global call to action

On March 27, Adherence and its ATLAS platform will offer the world’s first real-time snapshot of global medication adherence, powered by MMAS assessments. The event will collect adherence data from every inhabited continent, providing a powerful lens into the behaviors and challenges that impact health outcomes globally.

The World Adherence Day initiative has already garnered participation commitments from several teaching hospitals and universities worldwide. Students, residents, and community health workers will conduct MMAS assessments within their local communities, pharmacies, and hospitals, generating meaningful data to inform future healthcare policies and practices.

Those interested can get involved in the following ways:

Explore the ATLAS™ adherence map and watch real-time adherence data unfold live at tinyurl.com/atlasadherence (password: adherenceday2025).
Contribute to the Global Study by participating in the MMAS-8 survey at tinyurl.com/atlasmmas.
Universities, sponsors, and healthcare organizations are invited to take part in this historic initiative and gain early insights from this transformative data set. Sign up at tinyurl.com/atlasregister

For more information on Athena by Cliniphai, visit: www.cliniphai.com.

About Cliniphai

Cliniphai is an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences that accelerates innovation, streamlines operations, and enables smarter decision-making across the entire value chain. The company’s flagship platform, Athena, is an AI-powered clinical translation and localization tool focused on delivering secure, compliant, and high-quality solutions for life sciences. Founded by industry veterans in clinical trial execution, technology development, and regulatory compliance, Cliniphai is redefining how organizations approach AI in life sciences—without compromising accuracy, security, or compliance. For more information, visit: https://www.cliniphai.com/.

About Adherence

Adherence, operated by Philip Morisky and his team of data scientists, is a global leader in advancing medication adherence science. Adherence develops and manages the many derivatives of the Morisky Medication Adherence Scales (MMAS), the internationally recognized gold standard for measuring and improving medication adherence in clinical trials, healthcare systems, and public health initiatives. Validated in thousands of peer-reviewed studies and used in over 100 countries, the MMAS provides healthcare professionals, researchers, and policymakers with reliable, actionable insights that enhance patient outcomes and support evidence-based decision-making. For more information, visit https://www.adherence.cc

Media Contact

Don F. McLean, McLean Media

+1-734-716-4162

###

Cliniphai Creates AI-Powered Clinical Trial Localization and Translation Technology of the Future Designed for the Life Sciences Industry

Written by Donald McLean on March 21, 2025. Posted in Uncategorized. No Comments on Cliniphai Creates AI-Powered Clinical Trial Localization and Translation Technology of the Future Designed for the Life Sciences Industry

Named Athena, it combines multiple LLMs with human-in-the-loop control

Great Falls, Montana and Kyiv, Ukraine (March 20, 2025) – Cliniphai, an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, today announces the launch of Athena, an AI-driven clinical localization and translation workbench designed specifically for the life sciences, healthcare, and pharmaceutical industries. Unlike standard translation engines, Athena provides an adaptive, guided, and fully transparent process to provide high-quality, regulatory-compliant translations that enhance both speed and accuracy.

Built to meet the needs of eCOA providers, clinical trial site and recruitment organizations, and clinical research organizations (CROs), Athena serves as a best-in-class AI-powered workbench that combines multiple large language models (LLMs). Athena maintains human-in-the-loop control to ensure the highest translation quality in a guided, not automated experience.

“My partners and I set out to build a tool that we needed – that our industry needs – to truly solve the challenges of clinical translation and localization,” said Jason Martin, MS, MBA, Chairman and Co-Founder at Cliniphai. “Athena is our answer. This is the only workbench of its kind that is designed to empower expert translators with AI-driven support, guided parsing, and full workflow automation. You can’t rely solely on machines in the life sciences industry, but with Athena, we are making it easier to achieve accuracy, consistency, and compliance at an unexpected pace.”

Key Differentiators That Set Athena Apart

Athena by Cliniphai combines AI-driven efficiency with human expertise, delivering a guided, adaptive, and compliance-focused translation experience tailored for life sciences. Key differentiators include the following:

Adaptive and Context-Aware Translations: Athena understands dialects, terminology, and context, and it gives users the ability to add instructions, choose available dialects, simplify language, and maintain consistency across large-scale projects.
Auto-Review: Athena automates the guidance and management process, maintaining tone, terminology, and compliance.
Accelerated Rescue Translations: Athena is designed to compress timelines and handle high-stakes, large-scale translation projects on tight turnarounds.
Best-in-Class Service: Built with clever integration of proprietary AI-enabled services on top of industry leading workflow management, Athena can operate with scale to ensure smooth project handling, customer support, and compliance.
Powered by Real-World Expertise: Cliniphai has built deep operational experience across clinical studies and is working with trusted partners that have spent decades ensuring linguistic accuracy in life sciences.
Seamless API Integration: Fully accessible via API, Cliniphai allowing life sciences companies to integrate Athena directly into their existing platforms, workflows, and regulatory processes.
On-Premise Deployment for Maximum Security: Athena can be installed directly within your organization’s infrastructure, allowing you to maintain complete control over data, eliminate external communication delays, and integrate seamlessly with your existing workflows and processes.

A new standard for translations

Cliniphai’s globally-located team speaks more than 10 languages in-house, bringing a global perspective to clinical and regulatory translation challenges. Additionally, the company’s 17-person development team is actively refining the software development lifecycle and using AI, combined with the proper scientific acumen, to exceed industry expectations.

“Poor translations have led to millions in lawsuits in our industry, and Cliniphai is committed to ensuring this never happens to its customers. No matter the translation or localization need, it shouldn’t be a slow, painful process. So far, the feedback from our testing group has been very positive,” added Vladimir Mats, PhD, CEO and Co-Founder, Cliniphai. “Our goal from day one was to redefine clinical translation and localization workflows for the pharmaceutical and biotech industry, and today it becomes a reality.”

Martin added, “The team explored multiple entry points as an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, and after various prototypes, we decided to build translation and localization first. This is simply the beginning, and Cliniphai’s future is very bright.

Ask for a demonstration of Athena by Cliniphai at www.cliniphai.com.

About Cliniphai

Media Contact

Don F. McLean, McLean Media

+1-734-716-4162

###